Why FIH oncology trials fail before they start
A perspective on site mix, protocol assumptions, activation delays, and hidden execution risk.
Insights
Signals worth reviewing before early oncology execution.
A practical resource page for public research, oncology conference signals, and our perspective on FIH execution risk. Public Apex AI articles and official sources such as ASCO, ESMO, AACR, and SITC are available as filterable source material with original links preserved.
Featured perspectives
Start with the questions sponsors usually discover too late.
These short editorial themes give the Insights page a stable point of view even when external public-source feeds are temporarily unavailable.
Site-level activation risk vs traditional feasibility
Why averages and prestige-based KOL selection can miss the operational tails that matter.
China innovation drugs going global
How global development strategy, region selection, and trial design affect credibility outside China.
How oncology site selection should differ by mechanism
Why ADCs, bispecifics, KRAS, CAR-T, radioligands, DDR assets, and TKIs should not use the same site logic.
Article library
Public research and oncology conference signals
A unified library of public Apex AI articles and official oncology meeting sources such as ASCO, ESMO, AACR, and SITC. Filter by source, topic, or keyword; cards preserve public metadata and official source links only.
Source: Conference articles · Topic: Official news release · 9 articles · 10 per page
Men May Be More Likely Than Women to Receive Later-stage Diagnoses for Many Cancer Types in the United States
Researchers say the study’s findings, published in Cancer Epidemiology, Biomarkers & Prevention, could provide insight into the discrepancies in cancer outcomes between men and women. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
Open official source
AACR Statement and Call to Action Concerning OMB Proposal to Rewrite the Rules for Scientists and Physicians Who Are Improving Pu...
The American Association for Cancer Research (AACR) is deeply concerned that the recent action of the White House Office of Management and Budget (OMB) to propose a new set of regulations on how federal grants... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
Open official source
AACR Names Matthew Vander Heiden, MD, PhD, FAACR, as Editor-in-Chief of the Journal Cancer Discovery
The American Association for Cancer Research (AACR) has appointed Matthew Vander Heiden, MD, PhD, FAACR, as editor-in-chief of Cancer Discovery. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
Open official source
AACR Releases Cancer Disparities Progress Report 2026
The report features latest statistics, including promising signs of progress, and 10 compelling personal stories. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
Open official sourceAdding a Lower Cutoff Value for CA19-9 May Identify Additional High-risk Cases of Pancreatic Cancer
CA19-9 is a biomarker whose levels often correlate with pancreatic cancer stage and prognosis, according to a study published in Clinical Cancer Research. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
Open official sourceEmerging Frontiers in Oncology to Support AACR and Early-Career Investigators Through Annual Oncology Summit
The American Association for Cancer Research (AACR) today thanked Emerging Frontiers in Oncology (EFO) for its support of the cancer research workforce through fundraising associated with the 8th Annual Emergi... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
Open official sourceEarly Myocarditis Onset After Immunotherapy May Predict Treatment-related Fatality
Co-occurrence of myocarditis with myositis and myasthenia gravis may also increase risk of death. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
Open official sourceExposure to Wildfire Smoke May Be Linked To Increased Risk of Developing Several Cancers
Exposure to wildfire smoke was associated with a significantly increased risk of lung, colorectal, breast, bladder, and blood cancer. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
Open official sourceIntralesional Nivolumab May Be Effective Against Precancerous Oral Lesions
The treatment preserved quality of life. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
Open official source